Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2024-01-08 Director's Dealing
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Nadav Kidron
Director's Dealing Classification · 98% confidence The document is a filing from ORAMED PHARMACEUTICALS INC, reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange. The key indicator is the line: "Attached hereto is a report on *Form 4 - Nadav Kidron*". Form 4 filings in the US context (which this company seems to reference alongside Israeli regulations) relate to insider transactions (directors' or officers' changes in holdings). Reviewing the provided definitions, 'Director's Dealing' (Code: DIRS) aligns best with Form 4 filings, which report personal share transactions by company directors and executives. Although the document is short and announces an attachment, the specific nature of the attached form (Form 4) points strongly to DIRS rather than the general 'Report Publication Announcement' (RPA) or 'Regulatory Filing' (RNS). The signatory is the Chief Legal Officer & Secretary, which is typical for insider transaction reports.
2024-01-08 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Miriam Kidron
Director's Dealing Classification · 99% confidence The document explicitly begins with "# **FORM 4**" and includes the header "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934". Form 4 is the standard SEC filing used by insiders (officers, directors, 10% owners) to report changes in their beneficial ownership of company securities. This directly corresponds to reporting personal share transactions by company directors and executives, which is defined as 'Director's Dealing' (DIRS) in the provided schema. Although the SEC filing itself is Form 4, the closest functional category provided is DIRS.
2024-01-08 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Miriam Kidron
Director's Dealing Classification · 98% confidence The document explicitly states it is an 'Other Report or Announcement' filed under Regulation 5 of the Securities Regulations concerning 'Periodic and Immediate Reports of Foreign Corporation'. Crucially, it states: 'Attached hereto is a report on *Form 4 - Miriam Kidron*' and references a PDF file. Form 4 filings in the US context typically relate to insider transactions (directors' or officers' changes in beneficial ownership). This aligns directly with the definition of Director's Dealing (DIRS). Since the document is an announcement attaching the actual Form 4, and Form 4 is the standard mechanism for reporting insider trades, the classification should be DIRS. The document length is short (1882 chars), supporting the idea that it is an announcement rather than the full report itself, but the specific content points strongly to DIRS over a generic RPA or RNS.
2024-01-08 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Leonard Sank
Director's Dealing Classification · 98% confidence The document explicitly begins with the header "FORM 4" and references the "UNITED STATES SECURITIES AND EXCHANGE COMMISSION". It details a "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES" filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. This specific SEC filing form (Form 4) is used by insiders (directors, officers, or 10% owners) to report transactions in the company's securities. This type of filing is not explicitly listed in the provided definitions, but it is a mandatory regulatory filing concerning insider transactions, which aligns most closely with the concept of Director's Dealing (DIRS) or a general Regulatory Filing (RNS). Since 'DIRS' specifically covers 'Report of personal share transactions by company directors and executives (insider trades)', and this document is a Form 4 detailing such transactions (Acquisitions of Common Stock by a Director/Officer), DIRS is the most precise classification. It is not a 10-K, ER, or IR, as it is a specific transaction report, not a comprehensive financial report.
2024-01-08 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Leonard Sank
Director's Dealing Classification · 95% confidence The document is a short regulatory filing announcement from ORAMED PHARMACEUTICALS INC, reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange. The key content states: 'Attached hereto is a report on *Form 4 - Leonard Sank*'. Form 4 filings in the US context (mentioned via NASDAQ CM and US address) relate to insider transactions (directors' or executives' trades). This directly corresponds to the definition of Director's Dealing (DIRS). Although Form 4 is an insider trade report, the document itself is an announcement stating the report is attached, which might suggest RPA or RNS based on the 'MENU VS MEAL' rule. However, since the content explicitly names a specific, well-defined insider transaction form (Form 4), and the classification scheme has a specific code for Director's Dealing (DIRS), DIRS is the most accurate classification for the *subject matter* being announced. Given the short length and the nature of attaching a specific report, it functions as a notification of a DIRS event. I will classify it as DIRS as it is a specific insider transaction report notification, which is more precise than the general RPA/RNS fallback.
2024-01-08 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Joshua Hexter
Director's Dealing Classification · 100% confidence The document explicitly begins with '# **FORM 4**' and references the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION' and 'STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES'. Form 4 is the standard SEC filing used to report insider transactions (changes in beneficial ownership of securities) by directors, officers, and 10% owners. This directly corresponds to the definition of Director's Dealing (insider trades). Although the content involves securities transactions, the specific SEC form type (Form 4) is a highly specific regulatory filing for insider transactions, which aligns best with the 'Director's Dealing' category (DIRS) rather than a general regulatory filing (RNS) or a general capital change (SHA/POS). The document is a direct report of insider activity, not an announcement of a report (RPA).
2024-01-08 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.